抗癌平丸联合经导管肝动脉化疗栓塞术治疗中晚期肝癌的系统评价

摘要

OBJECTIVE: To systematically review the clinical efficacy of Kang 'aiping pills combined with transcatheter arterial chemoembolization ( TACE ) in treatment of intermediated or advanced liver cancer .METHODS:Randomized controlled trials on Kang 'aiping pills combined with TACE ( observation group ) and TACE alone ( control group) in respective treatment of intermediated or advanced liver cancer were involved by retrieving Wanfang , CBM, CNKI, VIP, PubMed, Airiti Library in Taiwan and HKU Scholars Hub , methodological quality evaluation was conducted after extracting data , and RevMan 5.3 was adopted to carry out Meta analysis .RESULTS: 3 studies including 776 patients were involved .Results of Meta analysis indicated that the combined treatment of Kang 'aiping pills and TACE can significantly promote the short-term effective rate (OR=2.18, 95％CI=1.48-3.22, P<0.0001), survival rate in 1 year (OR=1.87, 95％CI=1.30-2.70, P=0.0008), survival rate in 2 years (OR=2.03, 95％CI=1.41-2.92, P=0.0001) and improvement rate of life quality ( OR =2.87, 95％CI =1.35-6.11, P =0.0006 ) for patients with intermediated or advanced liver cancer compared with those of the control group , with statistically significant differences . CONCLUSIONS:The combined treatment of Kang 'aiping pills and TACE can significantly improve short-term efficacy for patients with intermediated or advanced liver cancer , promote survival rate and life quality .%目的:系统评价抗癌平丸联合经导管肝动脉化疗栓塞术(transcatheter arterial chemoembolization,TACE)治疗中晚期肝癌的临床疗效.方法:计算机检索万方数据、中国生物医学文献数据库、中国知网、中文科技期刊数据库、Pubmed、台湾学术文献数据库Airiti Library及香港大学学术库等,纳入有关抗癌平丸联合TACE(观察组)与单纯TACE(对照组)分别治疗中晚期肝癌的随机对照试验,提取资料并进行方法学质量评价后,采用RevMan 5.3软件进行文献荟萃(Meta)分析.结果:纳入3篇文献,共776例患者.Meta分析结果显示,与对照组比较,抗癌平丸联合TACE治疗可以显著提高中晚期肝癌患者的近期有效率(OR=2.18,95％CI=1.48～3.22,P<0.0001)、1年生存率(OR=1.87,95％CI=1.30～2.70,P=0.0008)、2年生存率(OR=2.03,95％CI=1.41～2.92,P=0.0001)和生活质量改善率(OR=2.87,95％CI=1.35～6.11,P=0.0006),差异均有统计学意义.结论:抗癌平丸联合TACE治疗可以改善中晚期患者的近期疗效,提高生存率和生活质量.